Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies

Detalles Bibliográficos
Autores principales: Shimizu, Toshio, Kuboki, Yasutoshi, Lin, Chia-Chi, Yonemori, Kan, Yanai, Tomoko, Faller, Douglas V., Dobler, lwona, Gupta, Neeraj, Sedarati, Farhad, Kim, Kyu-pyo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217764/
https://www.ncbi.nlm.nih.gov/pubmed/35412171
http://dx.doi.org/10.1007/s11523-022-00881-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217764/
https://www.ncbi.nlm.nih.gov/pubmed/35412171
http://dx.doi.org/10.1007/s11523-022-00881-2

Ejemplares similares